- recruitingTherapeutic exploratory (Phase II)
Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat)
This study is looking at a new combination of medicines to wake up 'sleeping' HIV in the body. By waking up the virus, the hope is that current treatments can then clear it more effectively. It's for adults with HIV-1, aiming to find better ways to manage the virus.
Netherlands - recruitingTherapeutic use (Phase IV)
Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)
This study looks at a medicine called fostemsavir (Rukobia) for adults living with HIV who have few treatment choices left. Researchers want to see if switching from an older type of HIV medicine to fostemsavir safely keeps the virus under control over 48 weeks without causing troublesome side effects.
Italy · Spain - authorisedTherapeutic exploratory (Phase II)
Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)
This study, called PLUTO, is investigating if a combination of three existing medicines (lenalidomide, pyrimethamine, and topiramate) can help us find a cure for HIV. It's an early-stage trial looking at how these drugs affect the HIV virus in people and how safe they are.
Netherlands - recruiting
Viral Infection of HSPC Impacts Hematopoiesis
This study looks at how viruses like HIV and COVID-19 might infect certain cells in our bone marrow. We want to see if these infected cells could become a long-term source of the virus and affect how our blood and immune system work.
France